Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network

Sietse M. Aukema, Eva Hoster, Andreas Rosenwald, Danielle Canoni, Marie-Hélène Delfau-Larue, Grzegorz Rymkiewicz, Christoph Thorns, Sylvia Hartmann, Hanneke Kluin-Nelemans, Olivier Hermine, Martin Dreyling and Wolfram Klapper

Key Points

  • TP53 expression (>50% positive cells) has shorter TTF and poor OS independent of both MIPI score and Ki67 index.


Currently, prediction of time to treatment failure (TTF) and overall survival (OS) in mantle cell lymphoma (MCL) is based on the clinical factors included in the Mantle Cell Lymphoma International Prognostic Index (MIPI), and proliferation is assessed by Ki67. However, TP53 and SOX11 immunohistochemistry might improve risk stratification. We performed SOX11 and TP53 immunohistochemistry on the so far largest published cohort of lymphoma specimens (n = 365). All patients were treated in prospective trials of the European MCL Network. In multivariate analyses, including MIPI and Ki67, SOX11 expression was not associated with TTF, but patients with low SOX11 expression had shorter OS. On the contrary, high TP53 expression was a strong predictor of TTF and inferior OS compared with low TP53 expression in univariate and multivariate analyses adjusting for MIPI score and Ki-67 index (hazard ratio [HR], 2.0; P = .0054 for TTF, and HR, 2.1; P = .068 for OS). In particular, patients with high TP53 expression (>50% positive lymphoma cells) had a shorter TTF and poor OS independent of both MIPI score and Ki-67 index. Thus, TP53 immunohistochemistry is a suitable test for routine diagnostic practice to assess MCL prognosis.

  • Submitted July 18, 2017.
  • Accepted November 21, 2017.
View Full Text